Paxlovid sales surge to $2.7 billion, beating expectations Pfizer raises annual revenue forecast for COVID products to $10.5 billion Pfizer management faces pressure from activist hedge fund ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pfizer has earned a nod from the U.S. regulator for another of its products in the indication. On Friday, the FDA signed ...

Pfizer (PFE) stock is lower in Tuesday's session even after the pharmaceutical giant beat top- and bottom-line expectations for its third quarter and raised its full-year outlook. Track all ...

Are you a print subscriber? Activate your account. By Tim Nudd - 1 hour 14 min ago By Adrianne Pasquarelli - 5 hours 42 min ago By Erika Wheless - 5 hours 42 min ago By Brian Bonilla - 5 hours 42 ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Two of Pfizer’s former executives have pulled out of hedge fund Starboard Value’s campaign to shake up ...

Starboard Value is knocking on Pfizer’sPFE-0.99%decrease; red down pointing triangle door, demanding the drugmaker make changes to improve performance. The problem for the company and its new ...

Pfizer’s stock has dropped in the double digits over three years. The company faces declines in sales of its coronavirus products and the loss of exclusivity of other major products. But over ...

Pfizer (NYSE: PFE) has been around for 175 years, selling a wide range of drugs in various treatment areas over time. But this pharma giant truly became a household name a few years ago.

When former executives team up with an activist investor to “help” a struggling company, it is often bad news for the current chief executive.

Starboard’s exact plan for Pfizer is not known but Wall Street’s frustration with the Viagra maker is. Under Bourla’s leadership, Pfizer bet all its chips on the Covid-19 pandemic and then ...

(Bloomberg) -- Pfizer Inc. has raised about £2.4 billion ($3.2 billion) from the sale of Haleon Plc shares, as it further reduces its stake in the UK consumer health company. The US ...